Drug intelligence / Profile preview

OMT-224

Development stage: Preclinical
Lead developer: OMEICOS Therapeutics
Modality: Small Molecules

Overview

OMT-224 is a preclinical-stage small molecule therapeutic being developed by OMEICOS Therapeutics. It is a synthetic analog of omega-3 fatty acid metabolites, specifically designed to mimic the biological activity of cytochrome P450-derived epoxyeicosanoids such as 17,18-epoxyeicosatetraenoic acid (17,18-EEQ). The drug is primarily being investigated for its potential to treat mitochondriopathies, including Leigh syndrome and MELAS syndrome, by stabilizing mitochondrial function and reducing oxidative stress. Additionally, OMEICOS is exploring the application of OMT-224 in oncology indications. The compound leverages the company's proprietary platform which focuses on the therapeutic potential of synthetic polyunsaturated fatty acid metabolites to modulate cellular metabolism and inflammatory pathways.

Beyond the preview

Go deeper on OMT-224.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OMT-224.

Explore the full profile